Currently holds positions in Adaptimmune Therapeutics PLC, Medimmune LLC and Ardelyx Inc
Position | Company | Period |
---|---|---|
Chief Operating Officer | Adaptimmune Therapeutics PLC | March 15, 2017 - |
Executive Vice President, General Counsel | Medimmune LLC | None - |
Independent Director | Ardelyx Inc | Oct. 26, 2015 - |
Executive Vice President, General Counsel | Infinity Pharmaceuticals Inc | Oct. 19, 2015 - Sept. 2, 2016 |
Acting Chief Operating Officer | Salix Pharmaceuticals Ltd | Jan. 30, 2015 - April 1, 2015 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
13,599
-40.2%
0.679,152 USD |
13,599 -40.2% | 0.67 | 9,152 USD | |
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
5,309
-40.5%
0.673,573 USD |
5,309 -40.5% | 0.67 | 3,573 USD | |
2024-01-12 | 2024-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
5,220
-39.9%
0.854,458 USD |
5,220 -39.9% | 0.85 | 4,458 USD | |
2024-01-12 | 2024-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,009
-39.6%
0.843,354 USD |
4,009 -39.6% | 0.84 | 3,354 USD | |
2023-01-17 | 2023-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,440
-37.9%
1.868,250 USD |
4,440 -37.9% | 1.86 | 8,250 USD | |
2023-01-12 | 2023-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,973
-38.0%
1.718,484 USD |
4,973 -38.0% | 1.71 | 8,484 USD | |
2023-01-04 | 2023-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,584
-38.3%
1.696,071 USD |
3,584 -38.3% | 1.69 | 6,071 USD | |
2022-01-18 | 2022-01-18 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,368
-37.3%
3.1913,942 USD |
4,368 -37.3% | 3.19 | 13,942 USD | |
2022-01-13 | 2022-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,248
-37.5%
3.547,967 USD |
2,248 -37.5% | 3.54 | 7,967 USD | |
2022-01-13 | 2022-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,770
-37.3%
3.5613,409 USD |
3,770 -37.3% | 3.56 | 13,409 USD | |
2022-01-05 | 2022-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,490
-37.3%
4.0614,184 USD |
3,490 -37.3% | 4.06 | 14,184 USD | |
2021-01-12 | 2021-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,234
-37.2%
6.1513,744 USD |
2,234 -37.2% | 6.15 | 13,744 USD | |
2021-01-05 | 2021-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,499
-37.4%
5.3318,642 USD |
3,499 -37.4% | 5.33 | 18,642 USD | |
2020-12-15 | 2020-12-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
B Purchase |
207,000
+266.0%
0.69143,824 USD |
207,000 +266.0% | 0.69 | 143,824 USD | |
2020-01-15 | 2020-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,397
-39.9%
5.1312,308 USD |
2,397 -39.9% | 5.13 | 12,308 USD | |
2020-01-07 | 2020-01-06 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,731
-39.8%
1.204,477 USD |
3,731 -39.8% | 1.20 | 4,477 USD | |
2019-01-16 | 2019-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,271
-37.8%
5.3712,194 USD |
2,271 -37.8% | 5.37 | 12,194 USD |